
## APPENDIX A: CLAIMS AFTER THE RESPONSE TO FINAL OFFICE ACTION

- 1. A homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region, wherein the homoconjugate has anti-neoplastic activity and wherein said monoclonal antibody has substantially no anti-neoplastic activity in an unconjugated form.
- 2. [Cancelled]
- 3. [Cancelled]
- 4. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.
- 5. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-Her2 monoclonal antibody.
- 6. [Cancelled]
- 7. The homoconjugate of claim 1, further defined as a homodimer.
- 8. The homoconjugate of claim 1, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.
- 9. The homoconjugate of claim 8, wherein the IgG is a mammalian IgG.
- 10. [Cancelled]
- 11. A method of making a homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region, comprising:

obtaining a first monoclonal antibody that does not comprise an Fc region; obtaining a second monoclonal antibody that does not comprise an Fc region; and conjugating the first monoclonal antibody to the second monoclonal antibody, wherein the first and second monoclonal antibodies have anti-neoplastic activity in a conjugated form and have substantially no anti-neoplastic activity in an unconjugated form.



22. The method of claim 11, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.

- 23. The method of claim 11, wherein the homoconjugate comprises a mammalian monoclonal antibody.
- 24. [Cancelled]
- 25. The method of claim 11, further consisting of: obtaining a third monoclonal antibody; and conjugating the third monoclonal antibody to the homoconjugate.

## 26-42. [Cancelled]

- 43. A pharmaceutical composition comprising a homoconjugate comprising a monoclonal antibody and a pharmaceutically acceptable carrier, wherein the monoclonal antibody does not comprise an Fc region and wherein the monoclonal antibody has anti-neoplastic activity in a conjugated form and has substantially no anti-neoplastic activity in an unconjugated form.
- 44. [Cancelled]
- 45. [Cancelled]
- 46. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.
- 47. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti- $\alpha$ Her2 monoclonal antibody.
- 48. [Cancelled]

- 49. The pharmaceutical composition of claim 43, wherein the homoconjugate is further defined as a homodimer.
- 50. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.
- 51. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a mammalian monoclonal antibody.
- 52. [Cancelled]